Different effects of angiotensin receptor blockade on end-organ damage in salt-dependent and salt-independent hypertension

Circulation

Volumn 114, Issue 9, 2006, Pages 905-911

  Maitland, Karlene ^b   Bridges, LaKeesha ^a   Davis, Wendell P ^c   Loscalzo, Joseph ^d   Pointer, Mildred A ^a  

^a NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NEW HAMPSHIRE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiotensin; Angiotensin II type 1 receptor blockers; End organ damage; Hypertension; Nitric oxide; Sodium chloride, dietary

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CANDESARTAN HEXETIL; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ENZYME INHIBITION; HEART FAILURE; HYPERTENSION; KIDNEY FAILURE; LOW DRUG DOSE; MALE; NONHUMAN; ORGAN INJURY; PATHOGENESIS; PRIORITY JOURNAL; PROTECTION; RAT; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TARGET ORGAN;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BLOOD PRESSURE; DISEASE PROGRESSION; HEART; HYPERTENSION; KIDNEY; MALE; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; SODIUM CHLORIDE, DIETARY; TETRAZOLES;

EID: 33748352551     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.622316     Document Type: Article

References (34)

1. Sheps SG. Overview of JNC VI: new directions in the management of hypertension and cardiovascular risk. Am J Hypertens. 1999;12:65S-72S.
2. McClellan W, Tuttle E, Issa A. Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension. Am J Kidney Dis. 1988;12:285-290.
3. JNC VI. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI): the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2415-2446.
4. Shulman N, Ford C, Hall W, Blaufox M, Simon D, Langford H, Schneider K. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the Hypertension Detection and Follow-up Program. Hypertension. 1989;13(suppl I):I80-I93.
5. Rostand S, Kirk K, Rutsky E, Pate B. Racial differences in incidences of treatment for end stage renal disease. N Engl J Med. 1982;306:1276-1279.
6. Weir MR. Salt intake and hypertensive renal injury in African-Americans: a therapeutic perspective. Am J Hypertens. 1995;8:635-644.
7. Weber M. Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension. Am J Hypertens. 1999;12:189S-194S.
8. Collins R, MacHahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. BMJ. 1994;14(suppl 1):S39-S46.
9. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease, part 1: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
10. He J, Whelton P. Elevated systolic blood pressure as a risk factor for cardiovascular and renal disease. J Hypertens. 1999;17(suppl):S7-S13.
11. Grimm R Jr, Flack J, Byington R, Bond G, Brugger S. A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis: the Multicenter Isradipine Diuretic Atherosclerotic Study (MIDAS). Drugs. 1990;40:38-43.
12. Samuelsson O, Wilhelmsen L, Svardsudd K, Pennert K, Wedel H, Berglund G. Mortality and morbidity in relation to systolic blood pressure in two populations with different management of hypertension: the study of men born in 1913 and the multifactorial primary prevention trial. J Hypertens. 1987;5:57-66.
13. Black H. Optimal blood pressure: how low should we go? Am J Hypertens. 1999;12:113S-120S.
14. Dawber T. The Framingham Study: Epidemiology of Atherosclerotic Disease. Cambridge, Mass: Harvard University Press; 1980.
15. Neutel J, Smith D, Weber M. Is high blood pressure a late manifestation of the hypertension syndrome? Am J Hypertens. 1999;12:215S-223S.
16. Seedat Y. Improvement in treatment of hypertension has not reduced incidence of rend-stage renal disease. J Hum Hypertens. 1999;13:747-751.
17. Trolliet MR, Rudd MA, Loscalzo J. Oxidative stress and renal dysfunction in salt-sensitive hypertension. Kidney Blood Press Res. 2001;24:116-123.
18. Trolliet MR, Forde P, Rudd MA, Loscalzo J. Effect of antioxidants on salt-induced hypertension and renal dysfunction. Hypertension. 2000;36:685c.
19. Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med. 2004;116:263-272.
20. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772-776.
21. Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ. 2004;329:1248-1249.
22. Cheung BM, Cheung GT, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension. J Hum Hypertens. 2006;20:37-43.
23. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-2031.
24. Schmidt BM, Schmieder RE. Aldosterone-induced cardiac damage: focus on blood pressure independent effects. Am J Hypertens. 2003;16:80-86.
25. Carey R, Wang Z-Q, Siragy H. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension. 2000;35:155-163.
26. Horiuchi M, Akishita M, Dzau V. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension. 1999;33:613-621.
27. Kakuchi J, Ichiki T, Kiyama S, Hogan B, Fogo A, Inagami T, Ichikawa I. Developmental expression of renal angiotensin II receptor genes in the mouse. Kidney Int. 1995;47:140-147.
28. 2) receptor protein in rat heart. Hypertension. 1998;32:78-83.
29. Senbonmatsu T, Ichihara S, Price E Jr, Gaffney FA, Inagami T. Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload. J Clin Invest. 2000;106:R25-R29.
30. Ito S, Arima S, Ren Y, Juncos LA, Carretero OA. Endothelium-derived relaxing factor/nitric oxide modulates angiotensin II action in the isolated microperfused rabbit afferent but not efferent arteriole. J Clin Invest. 1993;91:2012-2019.
31. 2 production in conscious rats. J Clin Invest. 1996;97:1978-1982.
32. Lim PO, Farquharson CA, Shiels P, Jung RT, Struthers AD, MacDonald TM. Adverse cardiac effects of salt with fludrocortisone in hypertension. Hypertension. 2001;37:856-861.
33. Rudd MA, Daumerie G, Maitland K, Bridges L, Yancey S, Cloutier T, Toolan G, Davis W, Huang P, Loscalzo J. Increased glomerular damage during high salt diet in eNOS deficient mice. Circulation. 2003;108:IV-269.
34. Ahn J, Varagic J, Slama M, Susic D, Frohlich ED. Cardiac structural and functional responses to salt loading in SHR. Am J Physiol. 2004;287:H767-H772.